Trial Profile

An Open-Label, Randomized, Single-Dose, Semi-Replicate, 4-Period, Crossover, Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tebipenem pivoxil (Primary)
Indications Haemophilus infections; Streptococcal infections; Urinary tract infections
Focus Pharmacokinetics
Sponsors Spero Therapeutics

16 Sep 2021 According to a Spero Therapeutics media release, data from the study will be presented at the Infectious Disease Society of America (IDSA) IDWeekTM 2021.
10 Aug 2020 Status changed from recruiting to completed.
10 Jun 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com